QUASAR2 patient characteristics
| Number | % | |
|---|---|---|
| Site | ||
| Colon | 930 | 89 |
| Rectum | 116 | 11 |
| Stage | ||
| II | 365 | 35 |
| III | 681 | 65 |
| Ethnicity | ||
| Caucasian | 1046 | 100 |
| Sex | ||
| Male | 593 | 57 |
| Female | 453 | 43 |
| Age, years | ||
| Median | 65 | |
| Minimum | 22 | |
| Maximum | 85 | |
| WHO performance status | ||
| 0–1 | 1046 | 100 |
| Treatment | ||
| Capecitabine (cap) | 496 | 47 |
| Cap+bevacizumab | 550 | 53 |
| Grade 3+adverse events | ||
| Global | 353 | 34 |
| Diarrhoea | 109 | 10 |
| HFS | 247 | 24 |
| Mucositis | 11 | 1 |
| Stomatitis | 12 | 1 |
| Vomiting | 15 | 1 |
| Neutropaenia | 22 | 2 |
| Thrombocytopaenia | 4 | 0 |